Vaxart stock price forecast both fundamental and sentiment-driven

Both fundamental and sentiment-driven models influence Vaxart’s current price forecast. Liquidity spikes over the past two sessions have hinted at accumulation patterns among swing traders. Today we will run through one way of estimating the intrinsic value of Vaxart, Inc. ( NASDAQ:VXRT ) by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex. We have appealed Nasdaq’s suspension and are scheduled to meet with their hearings panel on August 14, 2025. But based on our discussions and the realities of the market, we believe relisting is contingent on conducting a reverse stock split. Vaxart’s share price forecast often reflects FDA-related news cycles. With small-cap biotech ETFs showing a mild uptrend this month, any positive trial data could push VXRT above $0.80, though downside to $0.58 remains possible on delays.